Last reviewed · How we verify

NCT07446881: B06

A Phase 1 Study, to Evaluate the Effect of ADV7103 on Gastric pH Under Fed and Fasting Conditions in Adult Healthy Participants.

Completed Phase 1 Last updated 10 March 2026
What this trial tests

Phase 1 trial testing ADV7103 in EFFECT OF ADV7103 ON GASTRIC PH in 12 participants. Completed in 15 March 2025.

Timeline
25 February 2025
Primary endpoint
15 March 2025
15 March 2025

Quick facts

Lead sponsorAdvicenne Pharma
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment12
Start date25 February 2025
Primary completion15 March 2025
Estimated completion15 March 2025
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Advicenne Pharma — full company profile →

Who can join

Adults 18 to 45, any sex, with EFFECT OF ADV7103 ON GASTRIC PH or Distal Renal Tublular Acidosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This was a Phase 1, single-center, randomized, controlled, Latin-square, open-label study to evaluate the effect of ADV7103 on the gastric pH, after administering a single oral dose of ADV7103 in healthy adult participants under fasting and fed conditions

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of ADV7103

Trials testing the same drug.

Other Advicenne Pharma trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07446881.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing